Article Figures & Data
Figures
- FIGURE 1.
Competition assay with 3H-PK11195 and unlabeled PBR28, using tissue from donors with no history of neurologic disease. Each data point represents mean value of all subjects, and error bars represent SEM. Conc = concentration.
- FIGURE 2.
Competition assays with 3H-PK11195 and unlabeled TSPO ligand using brain tissue previously characterized as HAB, LAB, or MAB by PBR28 assays. Each data point represents mean value of at least 4 subjects, and error bars represent SEM. (A) Phenoxyphenyl acetamide derivatives. (B) Bicyclic linker derivatives. (C) Phenyl–isoquinolinecarboxamide derivatives. Conc = concentration; SB = specific binding.
- FIGURE 3.
Competition assays with 3H-PK11195 and unlabeled PBR111 in presence or absence of PBR28 (50 nM).
- FIGURE 4.
11C- PBR28 PET data from 32 healthy volunteers expressed as histogram with mixture model analysis showing 2 distributions for each measurement. (A) Volume of distribution. (B) Plasma free fraction. (C) Volume of distribution/plasma free fraction. Blue curves denote single-component solutions, and green and black curves denote 2-component solutions. For 2-component solutions, whereas different individuals are within each gaussian group (e.g., green) for 3 parameters, there was good agreement between A and B (74%) and A and C (66%).
- FIGURE 5.
TSPO ligands displayed in structural classes.
Tables
- TABLE 1
Competition Binding Studies with PK11195, PBR28, PBR06, PBR111, DPA713, and DAA1106
Ki (nM) of… Binding class PK11195* PBR28* PBR06 DPA713 DAA1106 PBR111 HABs 28.3 ± 4.0 (n = 6) 3.4 ± 0.2 (n = 6) 8.6 ± 2.0 (n = 5) 15.0 ± 2.2 (n = 5) 2.8 ± 0.3 (n = 4) 15.6 ± 3.7 (n = 5) LABs 22.3 ± 2.2 (n = 5) 188 ± 7.0 (n = 5) 149 ± 46.6 (n = 4) 66.4 ± 7.8 (n = 4) 13.1 ± 1.3 (n = 4) 61.8 ± 10.7 (n = 5) MABs 23.6 ± 5.5 (n = 4) Two receptors detected (n = 4): 4.0 ± 1.2 (high) and 313 ± 38 (low) Two receptors detected (n = 4): 13.4 ± 3.4 (high) and 176 ± 103 (low) 26.8 ± 2.9 (n = 4) 4.8 ± 0.4 (n = 4) 30.3 ± 4.1 (n = 4) Ki ratio of LAB to HAB 0.8 55 17 4.4 4.7 4.0 t test HAB vs. LAB P < 0.25 P < 0.0001 P < 0.011 P < 0.001 P < 0.001 P < 0.003 MAB vs. LAB P < 0.82 NA NA P < 0.003 P < 0.001 P < 0.04 MAB vs. HAB P < 0.50 NA NA P < 0.01 P < 0.005 P < 0.03 ↵* Data reproduced from Owen et al. (6).
NA = not applicable.
Data are expressed as mean ± SEM. All data in Table 1 were generated from donors B1–B15, inclusive.
Ki (nM) of… Reduction (%) in specific signal after block with PBR28 (50 nM) Binding class PBR111 PBR111 after block with PBR28 (50 nM) HABs 15.6 ± 3.7 (n = 5) Not measurable 69.0 ± 4.6 (n = 4) LABs 61.8 ± 10.7 (n = 5) 51.7 ± 12.2 (n = 4) 21.2 ± 4.8 (n = 4) MABs 30.3 ± 4.1 (n = 4) 54.4 ± 5.3 (n = 4) 49.3 ± 2.9 (n = 4) t test HAB vs LAB P < 0.003 NA P < 0.0004 MAB vs LAB P < 0.04 P < 0.84 P < 0.002 MAB vs HAB P < 0.03 NA P < 0.01 NA = not applicable.
Data are expressed as mean ± SEM.
Ligand LAB MAB HAB PBR28 1 28.2 55.3 PBR06 1 9.2 17.3 DAA1106 1 2.9 4.7 PBR111 1 2.5 4.0 DPA173 1 2.7 4.4 PK11195 1 0.9 0.8 MABs are assumed to express equal number of HAB and MAB sites. Receptor density is assumed to remain constant. Values are calculated as BPND relative to BPND of LABs.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant
- Mapping microglia and astrocytes activation in vivo using diffusion MRI
- [11C]PK11195-PET Brain Imaging of the Mitochondrial Translocator Protein in Mitochondrial Disease
- Neuroinflammation in cognitive decline post-cardiac surgery (the FOCUS study): an observational study protocol
- Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis
- Quantification of Macrophage-Driven Inflammation During Myocardial Infarction with 18F-LW223, a Novel TSPO Radiotracer with Binding Independent of the rs6971 Human Polymorphism
- In vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies
- Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study
- Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism
- PET studies of the glial cell marker TSPO in psychosis patients - a meta-analysis using individual participant data
- Parametric Binding Images of the TSPO Ligand 18F-DPA-714
- Pharmacokinetic Analysis of 11C-PBR28 in the Rat Model of Herpes Encephalitis: Comparison with (R)-11C-PK11195
- Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?
- Structure of the mammalian TSPO/PBR protein
- Optimized Quantification of Translocator Protein Radioligand 18F-DPA-714 Uptake in the Brain of Genotyped Healthy Volunteers
- Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein
- In Vivo Quantification of Cerebral Translocator Protein Binding in Humans Using 6-Chloro-2-(4'-123I-Iodophenyl)-3-(N,N-Diethyl)-Imidazo[1,2-a]Pyridine-3-Acetamide SPECT
- New Targets for the Development of PET Tracers for Imaging Neurodegeneration in Alzheimer Disease
- Structure of the Mitochondrial Translocator Protein in Complex with a Diagnostic Ligand
- Quantification of the Specific Translocator Protein Signal of 18F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding
- Influence of TSPO Genotype on 11C-PBR28 Standardized Uptake Values
- Radiation Dosimetry and Biodistribution of the TSPO Ligand 11C-DPA-713 in Humans
- The Translocator Protein